

CURRICULUM VITAE

Bin Yi, Ph.D.

Current Title: Associate Research Scientist
Business Address: University of Georgia
College of Pharmacy
Department of Pharmaceutical & Biomedical Sciences
240 W. Green Street
Athens, GA 30602
Business Telephone: (706)-542-7410
Business email Address: bin.yi@uga.edu
Home Telephone: (504) 909-8172

Education:

Undergraduate

06/2002-06/2006 Bachelor of Engineering-Huaihua University, Huaihua, Hunan, China

Graduate

08/2006-06/2009 Master of Science-Kunming Institute of Zoology Chinese Academy of Sciences, Kunming, Yunnan, China

07/2009-06/2012 Ph.D.-Kunming Institute of Zoology Chinese Academy of Sciences, Kunming, Yunnan, China

Post-Doctoral Fellowship

08/2012-07/2016 Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

08/2016-12/2018 Louisiana State University Health Sciences Center Stanley Scott Cancer Center, New Orleans, LA, USA

Academic, Professional, and Research Appointments:

08/2012-07/2016 Post-Doctoral Fellowship-Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

08/2016-12/2018 Post-Doctoral Fellowship-Louisiana State University Health Sciences Center Stanley Scott Cancer Center, New Orleans, LA, USA

01/2019-07/2023 Assistant Professor-Louisiana State University Health Sciences Center Stanley Scott Cancer Center, New Orleans, LA, USA

01/2019-07/2023 Core Director, IVIS system, Louisiana Cancer Research Consortium, New Orleans, LA

08/2023-present Associate Research Scientist, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia

Membership in Professional Organizations:

2022-present Active Member, American Association for Cancer Research

Awards and Honors:

2004 Scholarship of Hunan Province Excellent Student

2008	Excellent Student and Outstanding Student Leader Award of Graduate University of Chinese Academy of Sciences
2010	Excellent Student of Graduate University of Chinese Academy of Sciences
2011	Award for CST Excellent Young Poster of Chinese Society for Cell Biology
2011	The Second Award from Academic Report of Annual Symposium of Key Laboratory of Animal Models and Human Disease Mechanism of Chinese Academy of Sciences and Yunnan,
2013	American Society of Clinical Oncology, awarded for Travel Grant for Best of ASCO Meeting in Chicago
2022	Research Incentive Award (\$6,678)

TEACHING EXPERIENCE AND RESPONSIBILITIES

Undergraduate, Medical, or Graduate Students Trained:

Research Advisor:

2014	David Bates Skinner, undergraduate student, College of Medicine, University of South Alabama; He presented Poster and won the Phi Kappa Phi undergraduate Phi te research award at University of South Alabama
2015	Stephen Ambrose, M.D./Ph.D. candidate, College of Medicine, University of South Alabama
2017	Nicholas D Fried, M.D./Ph.D. candidate, School of Medicine, Louisiana State University Health Science Center
2017	Sarah E Gardner, undergraduate student, School of Medicine, Louisiana State University Health Science Center
2018	Jacob Meariman, M.D./Ph.D. candidate, School of Medicine, Louisiana State University Health Science Center

School of Graduate Studies:

2019	Lecturer, Genet 258 Advanced Genomics, CRISPR/CAS system-- a novel tool for genome
2020	Judge, Medical Student Research Virtual Poster Symposium, SOM Honors Program

Professional Service:

2019-Present	Train LSUHSC personnel to operate IVIS imaging
--------------	--

RESEARCH AND SCHOLARSHIP

Grants and Contracts

Funded:

RO1CA271533

Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy

2022 -2027

Co-Investigator

Annual Amount: \$681,383

Funded:

COBRE Pilot Project
Targeting Neprilysin in cardiovascular disease by CRISPR/Cas 9 technology
10/2018 -07/31/2021
Principal Investigator
\$60,000

Journal Publications:

Refereed

1. **Bin Yi**, Hao Cheng, Dorota Wyczechowska, Qingzhao Yu, Li Li, Augusto Ochoa, Adam I. Riker, Yaguang Xi. 2021. Sulindac modulates the response of proficient MMR colorectal cancer to anti-PD-L1 immunotherapy. *Molecular Cancer Therapeutics*. 20(7): 1295-1304
2. Hongyou Zhao*, **Bin Yi***, Zhipin Liang, Ches'Nique Phillips, Hui-Yi Lin, Adam Riker. 2021. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer. *Genes & Diseases*. 8(3): 320-330. (*Co-first author).
3. Xiaolin Liu, Ruixia Ma, **Bin Yi**, Adam I. Riker, Yaguang Xi. 2021. MicroRNAs are involved in the development and progression of gastric cancer. *Acta Pharmacol Sin*. 42(7):1018-1026.
4. Ruixia Ma, **Bin Yi**, Adam I. Riker, Yaguang Xi. 2020. Metformin and Cancer immunity. *Acta Pharmacol Sin*. 41(11):1403-1409.
5. **Bin Yi***, Hong Chang*, Ruixia Ma, Xiangling Feng, Wei Li, Gary A. Piazza, Yaguang Xi. 2016. Inhibition of breast cancer cell motility with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGF β /miR-21 signaling. *Oncotarget*.7(7):7979-92. (*Co-first author).
6. Hong Chang*, **Bin Yi***, Ruixia Ma, Xiaoguo Zhang, Hongyou Zhao, Yaguang Xi. 2016. CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. *Sci. Rep*. 6:22312 (*Co-first author).
7. Jiangnan Liu, **Bin Yi**, Zhe Zhang, Yi Cao. 2016. CD176 single-chain variable antibody fragment (scFv) inhibits the adhesion of cancer cells to endothelial cells and hepatocytes. *Front Med*.10(2):204-11.
8. Ruixia Ma, **Bin Yi**, Gary A. Piazza, Yaguang Xi. 2015. Mechanistic Role of MicroRNA in Cancer Chemoprevention by Nonsteroidal Anti-inflammatory Drugs. *Curr Pharmacol Rep*. 1(3):154-160.
9. **Bin Yi**, Gary A. Piazza, Xiulan Su, Yaguang Xi. 2013. MicroRNA and Cancer Chemoprevention. *Cancer Prev Res*. 6(5):401-9.
10. **Bin Yi**, Zhe Zhang, Min Zhang, Reinhard Schwartz-Albiez, Yi Cao. 2013. CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia. *Oncol Rep*. 30(4): 1841-7.
11. **Bin Yi**, Min Zhang, R Schwartz-Albiez, Yi Cao. 2011. Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells. *Int J Oncol* 38(6): 1565-73.
12. **Bin Yi**, Hong Chang, Yi Cao. 2009. Improvement of Methods for Total RNA Extraction from Hepatocarcinoma Tissues and Cell Lines and Comparison of Reverse Transcription and cDNA Cloning Strategies. *Zoological Research*.30(5): 520-526.
13. Hong Chang, **Bin Yi**, Li Li, Feng Sun, Yi Cao. 2008. Methylation of Tumor Associated Genes in Tissue and Plasma Samples from Liver Diseases Patients. *Experimental and Molecular Pathology*. 85(2): 96-100.
14. Jian Zhang, **Bin Yi**, Lin Wei, Xianjing Wu. 2006. Investigation of method for isolation and identification of novel animal viruses. *China Animal Quarantine* 23(7):50-51 (in Chinese)
15. Xianghui Jiang, Xianjing Wu, Xinqun Huang, **Bin Yi**, Jian Zhang, Lin Wei. 2006. Effects of different fertilizers and ratio on the yield of underground stem of *Houttuynia cordata*. *Guangxi Agricultural Sciences* 6: 697-699 (in Chinese)

16. Jian Zhang, **Bin Yi**, Xianjing Wu. 2005. Application of *Houttuynia cordata* in livestock disease control. *Animal Husbandry and Veterinary Medicine* 11(2):41-42 (in Chinese)

Book Chapters:

1. **Bin Yi** and Yaguang Xi 2013. MicroRNA is A New Player for Cancer Chemoprevention. *MicroRNAs in Toxicology and Medicine*, Saura C. Sahu (Ed.), John Wiley & Sons
2. **Bin Yi**, Kristina Larter and Yaguang Xi 2021. CRISPR/Cas9 System to Knockdown MicroRNA *In Vitro* and *In Vivo*. In: Rederstorff M. (eds) Small Non-Coding RNAs. *Methods in Molecular Biology*, vol 2300. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1386-3_13
3. Kristina Larter, **Bin Yi**, and Yaguang Xi 2021. Genetic Editing of Long Non-Coding RNA Using CRISPR/Cas9 Technology Long Non-Coding RNAs. *Methods and Protocol*.

Published Abstracts:

1. **Bin Yi**, Xiaobo Li, Wenjun Du, Gary A. Piazza, Yaguang Xi. Let-7 brings new insights into chronic myeloid leukemia therapy. *2013 AACR Annual Meeting. Washington DC.*
2. **Bin Yi**, Ruixia Ma, Xiangling Feng, Zhiwei Xing, Xiaoguo Zhang, Gary Piazza, Yaguang Xi. MicroRNA improves the efficacy of imatinib on the treatment of chronic myeloid leukemia. *2014 AACR Annual Meeting. San Diego CA.*
3. **Bin Yi**, Xiangling Feng, Hong Chang, Ruixia Ma, Xiaoguo Zhang, Gary A Piazza, Yaguang Xi. SSA, a novel sulindac sulfide derivative, inhibits tumor cell growth and invasion in breast cancer. *2014 Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium.*
4. **Bin Yi**, Xingling Feng, Ruixia Ma, Xiaoguo Zhang, Hong Chang, Hongyou Zhao, Ziping Liang, Xi Chen, Xiuhua Hu, Gary Piazza, Yaguang Xi. SSA, a novel sulindac derivative, inhibits breast cancer cell invasion and migration. *2015 AACR Annual Meeting. Philadelphia PA.*
5. Hongyou Zhao, **Bin Yi**, Hong Chang, Zhipin Liang, Ruixia Ma and Yaguang Xi. Sulindac inhibition of colon tumor cell growth through miR-182/FOXO3a/CyclinG2 signaling. *2016 AACR Precision Medicine Series: Cancer Cell Cycle-Tumor Progression and Therapeutic Response. Orlando FL.*
6. **Bin Yi**, Hong Chang, Xiangling Feng, Ruixia Ma, Gary A. Piazza, and Yaguang Xi. Inhibition of breast cancer cell metastasis with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGF β /miR-21 signaling. *2016 AACR Precision Medicine Series: Cancer Cell Cycle-Tumor Progression and Therapeutic Response. Orlando FL.*
7. Zhipin Liang, Xiangling Feng, Hong Chang, **Bin Yi**, Ruixia Ma, Yaguang Xi. Sulindac inhibition of tumor cell transformation. *2016 AACR Precision Medicine Series: Cancer Cell Cycle-Tumor Progression and Therapeutic Response. Orlando FL.*
8. Hong Chang, **Bin Yi**, Ruixia Ma, Xiaoguo Zhang, Hongyou Zhao, Yaguang Xi. CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. *2016 AACR Annual Meeting. New Orleans LA.*
9. Zhipin Liang, **Bin Yi**, Hongyou Zhao, Ruixia Ma, Yaguang Xi. Let-7 mediates sulindac inhibition of tumor cell transformation. *2017 AACR Annual Meeting. Washington, DC. Philadelphia.*
10. Hongyou Zhao, **Bin Yi**, Zhipin Liang, Ruixia Ma, Yaguang Xi. Mir-182 is involved in sulindac anticancer activity in colon cancer. *2017 AACR Annual Meeting. Washington, DC. Philadelphia.*
11. **Bin Yi**, Ruixia Ma, Yaguang Xi. MicroRNA and triple negative breast cancer. *2018 AACR Annual Meeting. Chicago, IL.*

Scientific Presentations:

Scientific Poster Presentations at Local/Regional Meetings

1. **Bin Yi**, Xiaobo Li, Wenjun Du, Gary A. Piazza, Yaguang Xi. Let-7a provides a new therapeutic option for chronic myeloid leukemia. 7th Annual USA COM Research Forum, USA, Mobile, AL, 2013.
2. **Bin Yi**, Xiangling Feng, Hong Chang, Ruixia Ma, Xiaoguo Zhang, Gary A Piazza, Yaguang Xi. SSA, a novel sulindac derivative, inhibits breast cancer cell invasion and migration. 8th Annual USA COM Research Forum, USA, Mobile, AL, 2014.
3. **Bin Yi**, Xingling Feng, Ruixia Ma, Xiaoguo Zhang, Hong Chang, Hongyou Zhao, Ziping Liang, Xi Chen, Xiuhua Hu, Gary Piazza, Yaguang Xi. Inhibition of breast cancer cell metastasis with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGF β /miR-21 signaling. 9th Annual USA COM Research Forum, USA, Mobile, AL, 2015.
4. **Bin Yi**, Hongyou Zhao, Zhipin Liang, Ruixia Ma, Ches'Nique M. Phillips, Huike Yang, Xiaolin Liu, Yaguang Xi. Inhibition of colon cancer cell invasion and metastasis with the non-COX inhibitory activity of sulindac by suppressing miR-17/QKI axis. Louisiana Cancer Research Consortium, New Orleans, LA, 2017

Scientific Poster Presentations at National/International Meetings

1. **Bin Yi**, Xiaobo Li, Wenjun Du, Gary A. Piazza, Yaguang Xi. Let-7 brings new insights into chronic myeloid leukemia therapy. *2013 AACR Annual Meeting. Washington DC.*
2. **Bin Yi**, Ruixia Ma, Xiangling Feng, Zhiwei Xing, Xiaoguo Zhang, Gary Piazza, Yaguang Xi. MicroRNA improves the efficacy of imatinib on the treatment of chronic myeloid leukemia. *2014 AACR Annual Meeting. San Diego CA.*
3. **Bin Yi**, Xiangling Feng, Hong Chang, Ruixia Ma, Xiaoguo Zhang, Gary A Piazza, Yaguang Xi. SSA, a novel sulindac sulfide derivative, inhibits tumor cell growth and invasion in breast cancer. *2014 Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium.*
4. **Bin Yi**, Xingling Feng, Ruixia Ma, Xiaoguo Zhang, Hong Chang, Hongyou Zhao, Ziping Liang, Xi Chen, Xiuhua Hu, Gary Piazza, Yaguang Xi. SSA, a novel sulindac derivative, inhibits breast cancer cell invasion and migration. *2015 AACR Annual Meeting. Philadelphia PA.*
5. Hongyou Zhao, **Bin Yi**, Hong Chang, Zhipin Liang, Ruixia Ma and Yaguang Xi. Sulindac inhibition of colon tumor cell growth through miR-182/FOXO3a/CyclinG2 signaling. *2016 AACR Precision Medicine Series: Cancer Cell Cycle-Tumor Progression and Therapeutic Response. Orlando FL.*
6. **Bin Yi**, Hong Chang, Xiangling Feng, Ruixia Ma, Gary A. Piazza, and Yaguang Xi. Inhibition of breast cancer cell metastasis with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGF β /miR-21 signaling. *2016 AACR Precision Medicine Series: Cancer Cell Cycle-Tumor Progression and Therapeutic Response. Orlando FL.*
7. Zhipin Liang, Xiangling Feng, Hong Chang, **Bin Yi**, Ruixia Ma, Yaguang Xi. Sulindac inhibition of tumor cell transformation. *2016 AACR Precision Medicine Series: Cancer Cell Cycle-Tumor Progression and Therapeutic Response. Orlando FL.*
8. Hong Chang, **Bin Yi**, Ruixia Ma, Xiaoguo Zhang, Hongyou Zhao, Yaguang Xi. CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. *2016 AACR Annual Meeting. New Orleans LA.*
9. Zhipin Liang, **Bin Yi**, Hongyou Zhao, Ruixia Ma, Yaguang Xi. Let-7 mediates sulindac inhibition of tumor cell transformation. *2017 AACR Annual Meeting. Washington, DC. Philadelphia.*
10. Hongyou Zhao, **Bin Yi**, Zhipin Liang, Ruixia Ma, Yaguang Xi. Mir-182 is involved in sulindac anticancer activity in colon cancer. *2017 AACR Annual Meeting. Washington, DC. Philadelphia.*

Invited Presentations and Seminars:

Invited seminars – Regional/Local

1. Title: Mechanism of Let-7a over-expression sensitizing chronic myeloid leukemia to Imatinib; Time: October 16th, 2012; Location: USA Mitchell Cancer Institute
2. Title: Let-7a provides a new therapeutic option for chronic myeloid leukemia; Time: March 25th, 2014; Location: USA Mitchell Cancer Institute
3. Title: SSA, a novel sulindac derivative, inhibits breast cancer cell invasion and migration; Time: February 3rd, 2015; Location: USA Mitchell Cancer Institute
4. Title: Inhibition of breast cancer cell metastasis with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGF β /miR-21 signaling; Time: December 4th, 2015; Location: USA College of Medicine
5. Title: MiR-17 mediates sulindac inhibition of colon cancer metastasis; Time: May 5th, 2017; Location: Department of Genetics LSUHSC-New Orleans
6. Title: Functional polarization of tumor-associated macrophages by Quaking in breast cancer metastasis; Time: May 11th, 2018; Location: Department of Genetics LSUHSC-New Orleans
7. Title: Functional polarization of tumor-associated macrophages by Quaking in breast cancer metastasis; Time: May 15th, 2018; Location: Stanley Scott Cancer Center; Joint Lab Meeting for Breast Cancer Research in New Orleans
8. Title: Develop miRNA therapeutics for BCR-ABL (+) leukemia; Time: May 29th, 2018; Location: Stanley Scott Cancer Center; Joint Lab Meeting in Tulane University
9. Title: Sulindac improve response to PD-L1 antibody immunotherapy of CT26 colon tumor; Time: January 22nd, 2020; Location: Stanley Scott Cancer Center; P20 Pre-SPORE meeting

Editorial Posts and Activities:

Journal editorships or associate editorships

2017-present	Editorial Board , <i>Journal of Gene Therapy and Research</i>
2017-present	Editorial Board , <i>Annals of Cancer Research and Therapeutics</i>
2020-present	Editorial Board , <i>Journal of Genetics, Cellular and Molecular Biology</i>
2022-present	Editorial Board , <i>Molecular Medicine and Cancer Treatment</i>

Reviewer status

2015	<i>Medicine</i> (3x/yr), <i>OncoTargets and Therapy</i> (2x/yr), <i>Therapeutics and Clinical Risk Management</i> (6x/yr), <i>Drug Design, Development and therapy</i> (1x/yr), <i>Journal of Experimental & Clinical Cancer Research</i> (3x/yr), <i>Cancer Cell International</i> (1x/yr), <i>International Journal of Preventive Medicine Research</i> (1x/yr), <i>Oncology Reports</i> (1x/yr), <i>Tumor Biology</i> (2x/yr).
2016	<i>OncoTargets and Therapy</i> (2x/yr), <i>Cancer Cell International</i> (1x/yr), <i>Journal of Cancer Science & Therapy</i> (1x/yr), <i>Oncology letter</i> (1x/yr), <i>Molecular and Cellular Biochemistry</i> (1x/yr), <i>Medicine</i> (4x/yr), <i>CancerGroup</i> (1x/yr), <i>Tumor Biology</i> (1x/yr), <i>Oncotarget</i> (1x/yr), <i>International Journal of Oncology</i> (1x/yr).
2017	<i>Molecular Medicine Reports</i> (1x/yr), <i>Journal of Gynecology Research</i> (1x/yr), <i>Genes</i> (1x/yr), <i>International Journal of Oncology</i> (1x/yr), <i>Medicine</i> (1x/yr), <i>Infectious Disorders-Drug Targets</i> (1x/yr), <i>Molecular Cancer</i> (1x/yr), <i>Journal of Cancer Metastasis and Treatment</i> (1x/yr), <i>OncoTargets and Therapy</i> (1x/yr).

2018 *Molecular Cancer (5x/yr), Infectious Disorders - Drug Targets (1x/yr)*
2019 *Molecular Cancer (7x/yr), Scientific Report (2x/yr)*
2020 *Molecular Cancer (2x/yr)*
2021 *Frontiers in Genetics (1x/yr), Frontiers in Cell and Developmental Biology (1x/yr)*
2022 *Frontiers in Molecular Biosciences (1x/yr),*